Fiore is an early stage investor in FluGen, founded in 2007. FluGen is the emerging leader in the fusion of intradermal delivery and vaccine biology. The company has differentiating technologies that enable it to create value and compete in the large, rapidly growing influenza vaccine market. FluGen is actively and aggressively advancing a valuable product pipeline that provides the company unique competitive advantages in this market and addresses significant unmet customer needs. These products include FluGen’s live attenuated vaccine candidate, REDEE FLU™ and a novel, vaccine-loaded intradermal delivery technology.